Last reviewed · How we verify
Rapid-acting insulin analogs
At a glance
| Generic name | Rapid-acting insulin analogs |
|---|---|
| Sponsor | Emory University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers (PHASE2, PHASE3)
- Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin Delivery (NA)
- Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes (PHASE2, PHASE3)
- Afrezza® INHALE-1 Study in Pediatrics (PHASE3)
- INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes (PHASE4)
- Acarbose and Prandial Insulin for the Treatment of Gestational Diabetes Mellitus. (PHASE3)
- Closed Loop From Onset in Type 1 Diabetes (NA)
- The Effect of Bolus Speed of Rapid-Acting Insulin Analog Absorption and Action in Individuals With Type 1 Diabetes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rapid-acting insulin analogs CI brief — competitive landscape report
- Rapid-acting insulin analogs updates RSS · CI watch RSS
- Emory University portfolio CI